2011
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H, B F. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Annals Of Oncology 2011, 23: 632-638. PMID: 21693770, PMCID: PMC3331731, DOI: 10.1093/annonc/mdr297.Peer-Reviewed Original ResearchConceptsProgression-free survivalGood performance statusFirst-line therapyMetastatic breast cancerOverall survivalPerformance statusBreast cancerOlder womenLeukemia Group B StudySecond-line therapyImproved overall survivalDoses of paclitaxelEstrogen receptor-positive statusTolerability of paclitaxelToxic effectsBilirubin elevationPaclitaxel efficacyWeekly paclitaxelOlder patientsMetastatic sitesTumor responseSimilar efficacyPositive statusSpecific toxic effectsPatients
2003
Clinical differences among the aromatase inhibitors.
Ligibel JA, Winer EP. Clinical differences among the aromatase inhibitors. Clinical Cancer Research 2003, 9: 473s-9s. PMID: 12538503.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsAdjuvant settingLarge phase III trialsThird-generation aromatase inhibitorsFirst-line settingSecond-line therapyDisease-free survivalPhase III trialsMetastatic breast cancerMegesterol acetateATAC trialIII trialsMetastatic diseaseClinical differencesNonsteroidal agentsClinical significanceBreast cancerAromatase activityAnastrozoleLetrozoleStudy designTamoxifenTrialsExemestaneInhibitors
1999
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE, Winer EP, Tannock IF, Schwartz on behalf of the North American Vorozole Study Grou L. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical Oncology 1999, 17: 52-63. PMID: 10458218, DOI: 10.1200/jco.1999.17.1.52.Peer-Reviewed Original ResearchConceptsPostmenopausal advanced breast cancer patientsAdvanced breast cancer patientsPhase III trialsBreast cancer patientsMegestrol acetateIII trialsCancer patientsTreatment groupsRandomized phase III trialUpper respiratory tract infectionSecond-line therapyAdvanced breast cancerDiscontinuation of treatmentRespiratory tract infectionsAromatase inhibitor vorozoleQuality of lifeMore dyspneaPostmenopausal womenAdverse eventsHot flushesMedian durationObjective responsePartial responseTamoxifen treatmentTract infections